XenoPort Inc (XNPT)

7.07
0.05 0.71
Prev Close 7.02
Open 7.04
Day Low/High 7.02 / 7.07
52 Wk Low/High 3.35 / 7.86
Volume 2.62M
Avg Volume 1.64M
Exchange
Shares Outstanding 63.53M
Market Cap 449.13M
EPS -1.30
Div & Yield N.A. (N.A)
First Week of June 2016 Options Trading For XenoPort (XNPT)

First Week of June 2016 Options Trading For XenoPort (XNPT)

Investors in XenoPort Inc saw new options begin trading this week, for the June 2016 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Perilous Reversal Watch: XenoPort (XNPT)

Perilous Reversal Watch: XenoPort (XNPT)

Trade-Ideas LLC identified XenoPort (XNPT) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: XenoPort (XNPT) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: XenoPort (XNPT) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified XenoPort (XNPT) as a strong on high relative volume candidate

Why Xenoport (XNPT) Stock Is Spiking Today

Why Xenoport (XNPT) Stock Is Spiking Today

Xenoport (XNPT) shares are up nearly 20% after the company detailed its business restructuring plan.

Strong On High Volume: XenoPort (XNPT)

Strong On High Volume: XenoPort (XNPT)

Trade-Ideas LLC identified XenoPort (XNPT) as a strong on high relative volume candidate

XenoPort Announces Plan To Focus On Its Growing HORIZANT Business And Names Vincent J. Angotti Chief Executive Officer And Director

XenoPort Announces Plan To Focus On Its Growing HORIZANT Business And Names Vincent J. Angotti Chief Executive Officer And Director

XenoPort, Inc. (Nasdaq: XNPT) announced today a strategic shift to focus on and maximize the value of its commercial product, HORIZANT ® (gabapentin enacarbil) Extended Release Tablets.

XenoPort (XNPT) Is Strong On High Volume Today

XenoPort (XNPT) Is Strong On High Volume Today

Trade-Ideas LLC identified XenoPort (XNPT) as a strong on high relative volume candidate

Today's Weak On High Volume Stock: XenoPort (XNPT)

Today's Weak On High Volume Stock: XenoPort (XNPT)

Trade-Ideas LLC identified XenoPort (XNPT) as a weak on high relative volume candidate

XenoPort (XNPT) Stock Plunged After Psoriasis Drug's Negative Side Effects

XenoPort (XNPT) Stock Plunged After Psoriasis Drug's Negative Side Effects

XenoPort (XNPT) shares closed Tuesday's trading session down as the company's psoriasis drug XP23829 showed frequent, gastrointestinal-related side effects.

Short Interest Makes 12.4% Move For XNPT

Short Interest Makes 12.4% Move For XNPT

The most recent short interest data has been released by the NASDAQ for the 08/31/2015 settlement date, which shows a 569,300 share increase in total short interest for XenoPort Inc , to 5,155,677, an increase of 12.41% since 08/14/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Diarrhea Dings Xenoport Psoriasis Drug Study Results

Diarrhea Dings Xenoport Psoriasis Drug Study Results

An experimental pill from Xenoport reduced psoriasis skin symptoms significantly more than a placebo in a mid-stage study, but a high rate of diarrhea raises questions about the drug's future.

XenoPort Announces Positive Phase 2 Study Results For XP23829 As A Potential Treatment For Patients With Psoriasis

XenoPort Announces Positive Phase 2 Study Results For XP23829 As A Potential Treatment For Patients With Psoriasis

XenoPort, Inc. (Nasdaq:XNPT) announced today positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis.

XenoPort To Present At The Morgan Stanley Global Healthcare Conference

XenoPort To Present At The Morgan Stanley Global Healthcare Conference

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Morgan Stanley Global Healthcare Conference.

XenoPort To Present At The 2015 Wells Fargo Healthcare Conference

XenoPort To Present At The 2015 Wells Fargo Healthcare Conference

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2015 Wells Fargo Healthcare Conference.

Interesting XNPT Put And Call Options For October 16th

Interesting XNPT Put And Call Options For October 16th

Investors in XenoPort Inc saw new options begin trading this week, for the October 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the XNPT options chain for the new October 16th contracts and identified one put and one call contract of particular interest.

XenoPort (XNPT) Highlighted As Weak On High Volume

XenoPort (XNPT) Highlighted As Weak On High Volume

Trade-Ideas LLC identified XenoPort (XNPT) as a weak on high relative volume candidate

XenoPort Reports Second Quarter Financial Results

XenoPort Reports Second Quarter Financial Results

XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the second quarter and six months ended June 30, 2015.

XenoPort To Release Second Quarter Financial Results On August 5, 2015

XenoPort To Release Second Quarter Financial Results On August 5, 2015

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its second quarter financial results on August 5, 2015 at approximately 4:30 p.

First Week of March 2016 Options Trading For XenoPort (XNPT)

First Week of March 2016 Options Trading For XenoPort (XNPT)

Investors in XenoPort Inc saw new options become available this week, for the March 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trigger breakout trades and move much higher.

10 Worst Biotech Stocks in the NASDAQ

10 Worst Biotech Stocks in the NASDAQ

Some biotech stocks way underperformed in this red-hot sector.

3 Pharmaceutical Stocks to Sell Now

3 Pharmaceutical Stocks to Sell Now

Pharmaceutical companies face increased risks if they do not have enough new drugs in the pipeline to replace those with expiring patents.

XenoPort Announces Initiation By NIAAA Of Clinical Trial Of HORIZANT In Patients With Alcohol Use Disorder

XenoPort Announces Initiation By NIAAA Of Clinical Trial Of HORIZANT In Patients With Alcohol Use Disorder

XenoPort, Inc. (Nasdaq:XNPT) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) announced today that the NIAAA has initiated a clinical trial of HORIZANT ® (gabapentin enacarbil) Extended-Release...

Quant Picks: 3 Pharmaceutical Companies to Sell Right Now

Quant Picks: 3 Pharmaceutical Companies to Sell Right Now

Here are some of the worst companies TheStreet Quant Ratings says you should consider selling.

HORIZANT (gabapentin Enacarbil) Included In New Expert Recommendations On Prevention And Treatment Of RLS Augmentation

HORIZANT (gabapentin Enacarbil) Included In New Expert Recommendations On Prevention And Treatment Of RLS Augmentation

XenoPort, Inc. (Nasdaq:XNPT) reported today that new expert recommendations for the prevention and treatment of augmentation in patients suffering from restless legs syndrome (RLS) list gabapentin enacarbil as a first-line...

XenoPort To Present New Pooled Data Analyses On HORIZANT (gabapentin Enacarbil) At The 2015 SLEEP Annual Meeting

XenoPort To Present New Pooled Data Analyses On HORIZANT (gabapentin Enacarbil) At The 2015 SLEEP Annual Meeting

XenoPort, Inc. (Nasdaq: XNPT) announced today that pooled data analyses for HORIZANT ® (gabapentin enacarbil) Extended-Release Tablets, will be presented at the upcoming 29 th Associated Professional Sleep Societies...

Trade-Ideas: XenoPort (XNPT) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: XenoPort (XNPT) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified XenoPort (XNPT) as a strong on high relative volume candidate

XenoPort To Present At The Jefferies 2015 Global Healthcare Conference

XenoPort To Present At The Jefferies 2015 Global Healthcare Conference

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Jefferies 2015 Global Healthcare Conference.

XenoPort To Present New HORIZANT (gabapentin Enacarbil) Data At The American Pain Society 34th Annual Scientific Meeting

XenoPort To Present New HORIZANT (gabapentin Enacarbil) Data At The American Pain Society 34th Annual Scientific Meeting

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data for HORIZANT ® (gabapentin enacarbil) Extended-Release Tablets at the American Pain Society 34th Annual Scientific Meeting in Palm Springs, CA.

XenoPort Reports First Quarter Financial Results

XenoPort Reports First Quarter Financial Results

XenoPort, Inc. (Nasdaq: XNPT) announced today its financial results for the first quarter ended March 31, 2015.